Form 8-K - Current report:
SEC Accession No. 0001599298-24-000087
Filing Date
2024-05-01
Accepted
2024-05-01 08:18:44
Documents
30
Period of Report
2024-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20240501.htm   iXBRL 8-K 34179
2 EX-99.1 pressreleaseq1march2024.htm EX-99.1 154813
3 EX-99.2 a20240501q12024earningsc.htm EX-99.2 19838
7 a20240501q12024earningsc001.jpg GRAPHIC 80815
8 a20240501q12024earningsc002.jpg GRAPHIC 257959
9 a20240501q12024earningsc003.jpg GRAPHIC 117994
10 a20240501q12024earningsc004.jpg GRAPHIC 120353
11 a20240501q12024earningsc005.jpg GRAPHIC 119594
12 a20240501q12024earningsc006.jpg GRAPHIC 161619
13 a20240501q12024earningsc007.jpg GRAPHIC 129340
14 a20240501q12024earningsc008.jpg GRAPHIC 87076
15 a20240501q12024earningsc009.jpg GRAPHIC 134499
16 a20240501q12024earningsc010.jpg GRAPHIC 161642
17 a20240501q12024earningsc011.jpg GRAPHIC 120226
18 a20240501q12024earningsc012.jpg GRAPHIC 160921
19 a20240501q12024earningsc013.jpg GRAPHIC 116244
20 a20240501q12024earningsc014.jpg GRAPHIC 80815
21 newlogo_09072021.jpg GRAPHIC 17737
  Complete submission text file 0001599298-24-000087.txt   2931613

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20240501.xsd EX-101.SCH 1907
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20240501_lab.xml EX-101.LAB 21629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20240501_pre.xml EX-101.PRE 12512
33 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20240501_htm.xml XML 2735
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 650-460-8308
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 24900189
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)